Date: 2017-12-21
Type of information: Nomination
Compound: chairman of the board of directors
Company: Crispr Therapeutics (Switzerland - UK)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
Financial terms:
Latest news:
- • On December 21, 2017, Crispr Therapeutics announced the appointment of Dr. Rodger Novak, founder and former CEO of Crispr Therapeutics as Chairman of the Board of Directors. Dr. Novak will succeed Dr. Tony Coles, who has helped lead the company in the transition from its early phase to a clinical-stage public company. Dr. Coles will remain a senior advisor to Crispr Therapeutics.
- In addition to assuming the board chairmanship, Dr. Novak will continue to serve on the board of directors of Casebia Therapeutics, Crispr’s 50-50 joint venture with Bayer. Dr. Novak is a serial entrepreneur and co-founded Crispr Therapeutics in 2013. As an experienced pharmaceutical and biotechnology executive and former University Professor at the Vienna Biocenter in Austria, he brings a combination of scientific experience and a proven track record of successfully translating technologies into pharmaceutical products. Dr. Novak will work closely with the Board and leadership team to fulfill Crispr’s mission of pioneering a new class of transformative therapies for serious diseases.
Is general: Yes
